Isaac Payne, DO
Colon & Rectal Surgery · Mobile, ALNPI 1902168552
Payments from drug & device makers
What this record shows
This record is dominated by education: $113,600 of the $163,266 with a category attached, or 69.6%. Intuitive Surgical accounts for 99.5% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $104,714, more than ten times the $2,622 reported in 2019.
Across 249 payments — averaging $655.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$162K
- Covidien LP$186
- AbbVie$122
- TELA Bio, Inc.$88
- Johnson & Johnson$76
- Integra Lifesciences Corporation$46
- plus $258 from 11 others
What the payments were for
- Speaking & faculty fees$20,00012%
- Travel & lodging$21,28113%
- Food & beverage$8,3865%
- Education$113,60070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 216 | $162,490 |
| Covidien LP | 2 | $186 |
| AbbVie(2 entities) | 8 | $122 |
| TELA Bio, Inc. | 6 | $88 |
| Johnson & Johnson | 4 | $76 |
| Integra Lifesciences Corporation | 1 | $46 |
| Trevena, Inc. | 2 | $40 |
| Tersera Therapeutics LLC | 1 | $31 |
| Biom'up France SAS | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Davol Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Incyte Corporation | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Focal Therapeutics, Inc. | 1 | $16 |
| THD America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$158,052
- DA VINCI SP$2,250
How this compares
Too few colon & rectal surgery providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SutabSod Sulf/Pot Chloride/Mag Sulf | 66 | $10,495 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 151 | $2,641 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 97 | $1,509 |
| Neomycin Sulfate | 64 | $355 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 26 | $284 |
| Oxycodone Hcl | 48 | $182 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 42 | $162 |
| Metronidazole | 70 | $142 |
| LoperamideLoperamide Hcl | 13 | $125 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $75 |
| Potassium Chloride | 63 | $72 |
| Omeprazole | 14 | $51 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Mobile
- Paul RiderMobile$37K
- John HunterMobile$33K
- Leander GrimmMobile$1K
- Gregory KennedyBirmingham$21K
- Andrew MitchellHuntsville$8K
- Rachel SaboBirmingham$8K
- Javad GolzarianHuntsville$8K
- Jon RosserBirmingham$8K
- Stephen ClarkHuntsville$8K
- Mark ParkerBirmingham$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.